AVALO THERAPEUTICS, INC. Research and Development Expense
AVALO THERAPEUTICS, INC. (AVTX) reported Research and Development Expense of $2.50 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-05-13
- AVALO THERAPEUTICS, INC. research and development expense for the quarter ending 2021-03-31 was $2.50M.
- AVALO THERAPEUTICS, INC. research and development expense for the quarter ending 2019-03-31 was $3.40M, a 106.16% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense for the quarter ending 2018-06-30 was $1.08M, a 119.33% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense for the quarter ending 2018-03-31 was $1.65M, a 73.10% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense for fiscal 2018 was $5.79M, a 32.34% increase from fiscal 2017.
- AVALO THERAPEUTICS, INC. research and development expense for fiscal 2017 was $4.37M, a 56.92% decline from fiscal 2016.
- AVALO THERAPEUTICS, INC. research and development expense for fiscal 2016 was $10.15M, a 54.09% increase from fiscal 2015.
- AVALO THERAPEUTICS, INC. research and development expense for fiscal 2015 was $6.59M, a 46.19% decline from fiscal 2014.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $2.50M 10-Q · filed 2021-05-13 | ||||
| 2019-03-31 | $3.40M 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $5.79M 10-K · filed 2019-03-18 | ||||
| 2018-06-30 | $1.08M 10-Q · filed 2018-08-09 | $2.73M 10-Q · filed 2018-08-09 | $4.69M derived: sum of 3 quarters · filed 2019-05-09 | $5.66M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2018-03-31 | $1.65M 10-Q · filed 2019-05-09 | $3.61M derived: sum of 2 quarters · filed 2019-05-09 | $4.58M derived: sum of 3 quarters · filed 2019-05-09 | $5.07M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | $1.96M 10-K · filed 2018-04-02 | $2.93M derived: sum of 2 quarters · filed 2018-04-02 | $3.42M derived: sum of 3 quarters · filed 2018-08-09 | $4.37M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $965.00K 10-K · filed 2018-04-02 | $964.57K 10-Q · filed 2017-11-07 | $1.46M derived: sum of 2 quarters · filed 2018-08-09 | $2.41M 10-Q · filed 2017-11-07 | $3.18M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | $493.65K 10-Q · filed 2018-08-09 | $1.45M 10-Q · filed 2018-08-09 | $2.22M derived: sum of 3 quarters · filed 2018-08-09 | $6.80M derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | $953.07K 10-Q · filed 2018-05-11 | $1.73M derived: sum of 2 quarters · filed 2018-05-11 | $6.31M derived: sum of 3 quarters · filed 2018-05-11 | $8.81M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2016-12-31 | $773.00K 10-K · filed 2018-04-02 | $5.36M derived: sum of 2 quarters · filed 2018-04-02 | $7.86M derived: sum of 3 quarters · filed 2018-04-02 | $10.15M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $4.58M 10-K · filed 2018-04-02 | $4.58M 10-Q · filed 2016-11-08 | $7.08M derived: sum of 2 quarters · filed 2018-04-02 | $9.38M 10-Q · filed 2017-11-07 | $11.13M derived: sum of 4 quarters · filed 2018-04-02 |
| 2016-06-30 | $2.50M 10-K · filed 2018-04-02 | $2.50M 10-Q · filed 2016-08-15 | $4.80M 10-Q · filed 2017-08-14 | $6.55M derived: sum of 3 quarters · filed 2018-04-02 | $7.78M derived: sum of 4 quarters · filed 2018-04-02 |
| 2016-03-31 | $2.29M 10-K · filed 2018-04-02 | $2.29M 10-Q · filed 2016-05-16 | $4.04M derived: sum of 2 quarters · filed 2018-04-02 | $5.28M derived: sum of 3 quarters · filed 2018-04-02 | $7.16M derived: sum of 4 quarters · filed 2018-04-02 |
| 2015-12-31 | $1.75M 10-K · filed 2017-03-14 | $2.99M derived: sum of 2 quarters · filed 2017-03-14 | $4.86M derived: sum of 3 quarters · filed 2017-03-14 | $6.59M 10-K · filed 2018-04-02 | |
| 2015-09-30 | $1.24M 10-K · filed 2017-03-14 | $1.24M 10-Q · filed 2015-11-13 | $3.11M derived: sum of 2 quarters · filed 2017-03-14 | $4.84M 10-Q · filed 2016-11-08 | $7.09M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $1.88M 10-K · filed 2017-03-14 | $3.60M 10-Q · filed 2016-08-15 | $5.86M derived: sum of 3 quarters · filed 2017-03-14 | $10.23M derived: sum of 4 quarters · filed 2017-03-14 | |
| 2015-03-31 | $1.72M 10-K · filed 2017-03-14 | $3.98M derived: sum of 2 quarters · filed 2017-03-14 | $8.35M derived: sum of 3 quarters · filed 2017-03-14 | $11.21M derived: sum of 4 quarters · filed 2017-03-14 | |
| 2014-12-31 | $2.26M 10-K · filed 2016-03-23 | $6.63M derived: sum of 2 quarters · filed 2016-03-23 | $9.49M derived: sum of 3 quarters · filed 2016-03-23 | $12.24M 10-K · filed 2017-03-14 | |
| 2014-09-30 | $4.37M 10-K · filed 2016-03-23 | $4.37M 10-Q · filed 2015-11-13 | $7.23M derived: sum of 2 quarters · filed 2016-03-23 | $9.98M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $2.86M 10-K · filed 2016-03-23 | $5.61M derived: sum of 2 quarters · filed 2016-03-23 | |||
| 2014-03-31 | $2.75M 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | $8.91M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |